The therapeutic benefits of L-3,4-dihydroxyphenylalanine (L-DOPA) in Parkinson disease (PD) patients diminishes with the onset of abnormal involuntary movements (L-DOPA induced dyskinesia), a debilitating motor side effect. L-DOPA induced dyskinesia are due to altered dopaminergic signaling in the striatum, a brain region that controls motor and cognitive functions.
INTRODUCTION
The loss of substantia nigral projections neurons, which results in decreased dopamine levels in the striatum, is the principle cause of PD. A drug known as L-DOPA, a precursor of dopamine synthesis, effectively alleviates motor stiffness in PD, but its therapeutic benefits are markedly limited by its debilitating dyskinetic side effects. Previous studies have shown that L-DOPAinduced dyskinesia is mediated by the activation of ERK and mTORC1 signaling in the striatum [1] [2] [3] . The inhibitors of these signaling may prevent L-DOPA-induced dyskinesia without affecting the beneficial effects of L-DOPA on limb motion 3, 4 . Ras-GRF1, which is abundant in the cortex, hippocampus, and striatum, is also known to activate ERK in the striatum and regulate L-DOPAinduced dyskinesia 5 . We found that Rhes, a striatal-enriched GTPase/SUMO-E3-like protein, binds and activates mTORC1 signaling and promotes L-DOPA-induced dyskinesia 6 , consistent with those of an independent report 7 . However, the striatal regulators that mediate both ERK and mTORC1 signaling and L-DOPA-induced dyskinesia remain unknown.
RasGRP1, a guanine-nucleotide exchange factor (GEF) for H-Ras that signals ERK, is highly expressed in hematopoietic cells and is regulated by calcium and diacylglycerol [8] [9] [10] [11] . RasGRP1 is known to play a role in T-and B-cell proliferation and has been implicated in leukemia and lupus [11] [12] [13] [14] [15] . RasGRP1 is enriched in selected brain regions that control motor and cognitive functions, including the striatum 10 . Despite its high expression in brain regions, its role in neuronal functions remains unclear. Previously, we found that RasGRP1 interacts and acts as a GEF for Rhes and promotes amphetamine-induced hyperactivity via the striatal protein-protein complex known as Rhesactome 16 . Here, we have reported a major role for RasGRP1 in L-DOPA-induced dyskinesia and demonstrated that RasGRP1 is causally linked to L-DOPAinduced dyskinesia and robustly activates ERK and mTORC1 pathways in the striatum. Using high-end quantitative proteomic analysis of WT and RasGRP1 -/mice, we have identified multiple striatal targets downstream of RasGRP1 activation that may be involved in L-DOPA-decreased Parkinson symptoms as measured by the drag test (on day 3 and day 16, Fig. 1F ) and the turning test (day 12, Fig. 1G ). As expected, sham injections produced no defects in the drag test ( Supplementary Fig. 1 ). The open field or rotarod test was also used as an anti-Parkinson disease readout, but we did not see any difference in total distance travelled or rotarod test results between the genotypes and sham treatment ( Supplementary Figs. 2 and 3) . Thus, RasGRP1 promoted the adverse effects of L-DOPA but not its therapeutic motor effects.
Moreover, RasGRP1 KO mice displayed no significant changes in basal motor behavior or coordination 16 , as shown in Supplementary Figs 3-5 , which would not likely contribute much to the altered L-DOPA responses we observed.
RasGRP1 was upregulated during L-DOPA-induced dyskinesia and promoted ERK, mTOR, and GluR1 signaling in the striatum of dyskinetic mice. Research has shown that dopamine 1 (D1) and dopamine 2 (D2) receptors of medium spiny neurons (MSN) in the striatum may play different roles in L-DOPA dyskinesia. For example, Santini et al. showed that ERK and mTOR signaling selectively enhanced L-DOPA treatment in D1 containing neurons 3 . Consistent with these data, the stimulation of mTOR signaling by L-DOPA has been shown to be abolished by D1 antagonists and unaffected by D2 antagonists 3 .
Similarly, we found that Rhes, which is predominantly expressed in D1 and D2 MSN, promoted mTOR in L-DOPA-induced dyskinesia 6 . As RasGRP1 KO mice showed diminished dyskinesia, we tested WT and RasGRP1-KO striatal tissue on L-DOPA-induced ERK, mTOR, and other signaling in the striatum. We observed several findings related to signaling in our model. First, we confirmed that lesions produced more than a 60% loss of tyrosine hydroxylase (TH) + in both WT and RasGRP1 KO mice ( Fig. 2A, B) , which indicated the onset of PD-like symptoms.
Intriguingly, we found that RasGRP1 levels were upregulated after L-DOPA injection, consistent with a previous report in a rat model of L-DOPA-induced dyskinesia 19 (Fig. 2A, B ). This increase was dependent on L-DOPA administration, as we found no increase of RasGRP1 in 6-OHDA lesion vehicle control ( Supplementary Fig. 4 ). We measured mTORC1 activity according to levels of phosphorylation of ribosomal protein S6 kinase (S6K) at T389 and phosphorylation of S6 at S235/236 in vivo and phosphorylation of eukaryotic translation initiation factor 4E (eIF4E)binding protein 1 (4EBP1) (T37/46) at a site that primes p4EBP1 for subsequent activity phosphorylation at S65. We were unable to detect p4EBP1 S65, as the antibodies for this site did not work for brain lysate. We also found that mTORC2 activity, as measured by phosphorylation of Akt (S473), was upregulated in 6-OHDA-lesioned WT mice but not in RasGRP1 KO mice ( Fig. 2A, B ). Previous findings have shown that Akt S473 phosphorylation was upregulated in a monkey model of L-DOPA-induced dyskinesia 20 . In addition, pGlur1 S845, pERK (T202/Y204), and the PI3K target, pAkt (T308), were also highly upregulated in WT but not RasGRP1 KO mice ( Fig. 2A, B ). We found that Rheb and Rhes levels, were significantly downregulated in the lesion side of RasGRP1 KO mice ( Fig. 2, A, B ), consistent with our earlier report 16 , indicating that RasGRP1 may physiologically stabilize these proteins in the striatum.
Together, these biochemical studies indicated that a) RasGRP1 is upregulated in an L-DOPAdependent manner; b) RasGRP1 KO prevents the upregulation of L-DOPA-induced mTOR, ERK, Akt, Glur1 signaling in the striatum; and c) Rhes and Rheb, activators of mTOR, are downregulated in the striatum of RasGRP1 KO mice compared to WT mice during L-DOPAinduced dyskinesia.
RasGRP1 mediated mTOR signaling in a PI3K-dependent and ERK-independent manner.
Next, we examined the potential mechanisms by which RasGRP1 upregulation in L-DOPA induced dyskinesia promoted mTOR and ERK signaling. To do this, first, we transiently overexpressed RasGRP1 in HEK293 cells, which were transfected with a control vector (His) or His-RasGRP1 cDNA. Then, we incubated HEK293 cells in serum-free F12 medium with full amino acids (plus AA) or F12 medium that lacked L-leucine (minus AA), which is a potent inducer of mTORC1 21 . After 2 h, cells in minus-AA medium were re-stimulated with L-leucine (3 mM).
In full-AA conditions, compared to control cells, RasGRP1-expressing cells had twice to three times as much mTORC1 activity as measured by the phosphorylation of S6K at T389 (pS6K-T389) and p4EBP1-S65 ( Figs. 3 A, B) . In minus-AA medium, mTORC1 activity was 50% lower in RasGRP1 expressing cells yet was higher than the control. Upon re-stimulation with L-leucine for 15 min, mTORC1 activity rapidly returned to levels comparable with those in full-AA conditions. This indicated that RasGRP1 mediated AA-mediated mTORC1 activity. RasGRP1 expression induced the constitutive phosphorylation of ERK, which is not sensitive to amino acids ( Fig. 3C ).
Next, we tested the effects of ERK inhibition on RasGRP1-mediated AA-mTORC1 signaling.
While U0126, a potent inhibitor of mitogen-activated protein kinase (MEK) abrogated ERK signaling, it had negligible effects on RasGRP1-induced pS6K (Thr389) and p4EBP1 (Ser65, Fig. 3C ). However, rapamycin, the mTORC1 inhibitor, which did not alter RasGRP1-induced ERK signaling, markedly attenuated RasGRP1-induced AA-mTORC1 signaling ( Fig. 3D ). Like rapamycin, the PI3K inhibitor wortmannin abolished RasGRP1-induced mTORC1 signaling ( Fig.   3E ). Collectively, rapamycin and wortmannin but not U0126 blocked RasGRP1-induced mTORC1 activation (Fig. 3F ). The depletion of endogenous RasGRP1 using short hairpin RNA (shRNA) in HEK cells also diminished mTORC1 signaling ( Supplementary Fig. 5 ). Together, this data suggested that RasGRP1 physiologically activates mTORC1 signaling by regulating catalytically important residues on pS6K and p4EBP1 via a PI3K-sensitive pathway. In addition, using a pharmacological approach, we found no significant cross talk between ERK and mTORC1 signaling induced by RasGRP1.
RasGRP1 directly interacted with Rheb in the striatum.
As there was no cross talk, we predicted that RasGRP1 would activate ERK and mTORC1 signaling in two independent and parallel pathways. Research has shown that RasGRP1 can activate ERK via GTPase H-Ras 8, 10 , but we wondered how RasGRP1 activates AA-induced mTORC1. As Rheb, which directly binds and activates mTOR, mediates AA-induced mTORC1 activity 22 , we hypothesized that RasGRP1 may promote mTORC1 activity by interacting with Rheb in the brain. To test this, we co-immunoprecipitated Rheb and RasGRP1 from the brain's striatum. As hypothesized, Fig 3G shows that Rheb effectively co-immunoprecipitated with RasGRP1 and mTOR, a known Rheb interactor. Rheb also coprecipitated huntingtin, which was consistent with our previous report 23 . However, the RasGRP1 antibody appeared inefficient for immunoprecipitation, as it only moderately enriched RasGRP1 (Fig. 3G ). Next, we investigated whether RasGRP1 interacted directly with Rheb in vitro. Co-incubation of bacterially purified GST-FL-RasGRP1 and Rheb revealed their robust interaction ( Fig. 3H ). As shown in Fig. 3I , the interaction appeared strong with FL-RasGRP1 compared to the RasGRP1 GEF domain (1-470 amino acids, 11 . Thus, for the first time, we showed that RasGRP1 can directly interact with Rheb in the striatum. Collectively, this data suggested that RasGRP1 may promote mTORC1 activity in the brain via Rheb GTPase.
Quantitative striatal proteomic analysis of WT and RasGRP1 -/mice revealed novel

RasGRP1 targets with potential involvement in L-DOPA-induced dyskinesia.
To understand the mechanisms by which RasGRP1 might elicit L-DOPA-induced dyskinesia, we undertook quantitative and comparative proteomics profiling of WT and RasGRP1 KO striatum with high-resolution mass spectrometry coupled to liquid chromatography (LC-MS/MS) based on tandem mass tags (TMT) designed for phosphoprotein enrichment. We isolated the striatum 20 min after L-DOPA administration from three WT mice that showed severe dyskinesia and three RasGRP1 KO mice that showed no dyskinesia in response to L-DOPA in a PD model ( Fig. 4A ). We labelled each lysate with TMT labelled six-plex reagents (ThermoFisher) as indicated in Table 1 . Loading bias was minimal and was removed by normalizing it with the total peptide amount. We quantified 617 phosphorylated proteins in all groups. ANOVA results indicated eight proteins were significantly regulated between the comparison groups (B/A, C/A, and D/A) (FDR 0.10) and then Turkeys HSD was used as post hoc test to find out which pairs were different from each other (alpha = 0.05) ( Fig. 4B , data files S1, S2, S3). Similarly, ANOVA results indicated seventy four proteins were significantly regulated, out of 1121 proteins identified, between the comparison groups (B/A, C/A, and D/A) (FDR 0.10) and then Turkeys HSD was used as post hoc test to find out which pairs were different from each other (alpha = 0.05, Fig. 4B , data files S4, S5, S6). Ingenuity Pathway Analysis (IPA) revealed that signaling pathways related to glutamate-dependent acid resistance, a-adrenergic signaling, sirtuin signaling, ephrin signaling, and glutamate degradation, Huntington disease pathways, mitochondrial dysfunction targets, protein kinase A signaling, and others were highly significantly upregulated in WT but not in RasGRP1 KO striatum ( Fig. 4C , data file S7). As shown in Fig. 4D , selected phosphorylated and total proteins upregulated in the lesion side of WT but not in RasGRP1 KO striatum. We observed that the phospho-enrichment of phosphodiesterase 1c (Pde1c), total Pde2a, both with a dual-specificity for the second messengers, cAMP and cGMP 24, 25 , was higher in WT than RasGRP1 KO striatum. This had demonstrable relevance in L-DOPA-induced dyskinesia, because the cAMP pathway [26] [27] [28] and PDE activation have been linked to L-DOPA-induced dyskinesia in a mouse and monkey model of PD 29, 30 . The specific role of Pde1c and Pde2a in regulating L-DOPA-induced dyskinesia is unknown. Likewise, the phosphorylation of Comt, an enzyme that catalyzes the degradation of catecholamines (including the neurotransmitters L-DOPA, dopamine, and epinephrine) is upregulated in WT but not in RasGRP1 KO mice.
Inhibitors of Comt can enhance L-DOPA-induced dyskinesia in monkeys 31 , indicating that the upregulation of Comt is an adaptative response designed to degrade L-DOPA, a feature that is absent in RasGRP1 KO mice. GFAP upregulation is found in 6-OHDA rodent model of PD 32, 33 .
Similarly, we found a dramatic upregulation of GFAP in the lesion side of both WT and RasGRP KO, although it is slightly less in the KO striatum ( Fig. 4D ). Gad 1, also known as Gad 67 and Gad 2, also known as Gad 65, catalyze the production of gamma-aminobutyric acid (GABA) and are upregulated in WT but not in RasGRP1 KO striatum (Fig. 4D ). The loss of Gad 67 has diminished L-DOPA-induced dyskinesia in mouse models of PD 34 . We used Western blotting with a tested antibody to validate the upregulation of Gad 1, Gad 2, Gfap, Pde1c and Pde2a observed in quantitative LC/MS/MS in the lesioned area of WT mice but not in RasGRP1 KO striatum ( Fig. 4E ). However, not all proteins were downregulated in RasGRP1 KO mice. For example, complexin-1, visinin-like protein, glutamate dehydrogenase 1, guanine nucleotidebinding protein G (g) subunit alpha, and lactate dehydrogenase were upregulated in RasGRP1 KO mice but not WT mice (data file S6). Collectively, LC/MS/MS data indicated that RasGRP1 acts upstream in response to L-DOPA and regulates a specific but diverse set of proteins to promote L-DOPA-induced dyskinesia. This notion is strengthened by the fact that some of these proteins have been implicated in L-DOPA-induced dyskinesia in independent studies [29] [30] [31] .
DISCUSSION
After 10 years of treatment, more than 95% of PD patients who receive L-DOPA medication develop dyskinesia, an uncontrolled motor deficit for which no effective therapy exists. There is an immediate need to identify novel therapeutic targets for L-DOPA-induced dyskinesia. Our study demonstrated that RasGRP1 is a major therapeutic target, because our data indicated that a) RasGRP1 is induced upon L-DOPA administration, b) RasGRP1 is causally linked to L-DOPA-induced dyskinesia, and c) RasGRP1 physiologically mediates L-DOPA-induced activation of ERK and mTOR, which are linked to L-DOPA-induced dyskinesia. RasGRP1 is a better target, because although mTOR inhibitors, such as rapamycin, or ERK inhibitors, such as U0126, have been shown to prevent L-DOPA-induced dyskinesia in mouse models 3, 4, 7 , these drugs are strong inhibitors of protein synthesis and have associated toxicity. In addition, they broadly inhibit targets in unwanted regions. Further, RasGRP1 KO mice have no gross phenotype, and they are fertile and have no significant changes in the basal motor activity 16 , 35 . Thus, drugs blocking RasGRP1 or shRNA approaches to deplete RasGRP1 in adults may produce fewer adverse effects and strong beneficial effects in preventing L-DOPAinduced dyskinesia.
Our study showed that RasGRP1 induces two major pathways, ERK and mTOR signaling, in the striatum during L-DOPA-induced dyskinesia. Cell culture data demonstrated that there was no cross talk between ERK and mTORC1 signaling and suggested a role for PI3K in these interactions. We proposed a model to show how RasGRP1 might activate both ERK and mTOR pathways during L-DOPA-induced dyskinesia ( Fig. 5 ). We predicted that RasGRP1 would form complexes with more than one small GTPase in the striatum during L-DOPA-induced dyskinesia ( Fig. 5 ). For example, upregulated RasGRP1 can form two kinds of GEF complex, a RasGRP1-Ras complex and a RasGRP1-Rheb complex, to activate ERK and mTOR signaling, respectively. This notion was consistent with the actions of other GEFs that activate multiple small GTPases 36, 37 . We predicted that upregulated RasGRP1 would act like a "master GEF"
for H-Ras, Rhes, and Rheb, deviating from the conventional notion that it acts as one GEF for one small GTPase. Such "GEF-GTPasome" complexes may afford the flexibility needed to develop the abnormal involuntary movements observed in L-DOPA-induced dyskinesia.
Supporting the notion of the existence of GEF-GTPasome we found that Rheb and Rhes both interacted directly with RasGRP1 in vitro (data not shown). We also predicted that RasGRP1 would be upregulated in response to dopamine D1 receptor super sensitivity in PD. To support this notion, we found that RasGRP1 protein levels were upregulated in the striatum of mice subjected to a cocaine-induced motor sensitization protocol 38 (data not shown). In addition to diminished ERK and mTORC1 signaling in RasGRP1 KO mice, we also found that pGluR1 (845), a target of protein kinase A (PKA) 39 was significantly diminished. PKA pathway is reported to be involved in L-DOPA induced dyskinesia 40 . Thus, RasGRP1 can also induce pGluR1 (S845) during L-DOPA-induced dyskinesia. presumably via Ras-cAMP signaling described in yeast 41 .
Our proteomics study revealed that RasGRP1 may exert a long-term effect on striatal protein composition to promote strong cellular, molecular, and anatomical alterations via regulating protein synthesis and/or posttranslational modifications. Such biological effects may promote sustained alterations in striatal signaling that could trigger debilitating L-DOPA-induced dyskinesia. A significant number of these putative RasGRP1 proteins could serve as potential targets of L-DOPA-induced dyskinesia. Instead of targeting each of these proteins individually, it may be worth directly targeting RasGRP1, whose deletion is tolerated in mice. Collectively, our study demonstrates that RasGRP1 has a major causal role in L-DOPA induced dyskinesia.
Thus, strategies aimed at blocking RasGRP1 may ameliorate L-DOPA-induced dyskinesia in PD patients.
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Materials and Methods
Reagents, plasmids, and antibodies. Chemicals and reagents were mainly purchased from Sigma. His-tagged rat CalDAG-GEFII and mouse Flag-CalDAG-GEFI were gift from Ann Graybiel (MIT). The myc-tagged RasGRP1 (pCMV-myc) and GST-tagged (pGEX-6P2) constructs were produced as described 16 
6-OHDA lesioning
Surgical procedures for unilateral 6-OHDA lesioning were performed as described previously 6 .
Briefly, mice were anesthetized deeply by administration of isoflurane. 
AIMs rating
Abnormal involuntary movements (AIMs) were scored using the rating system described before 6 . Briefly 
Drag test
Mice were habituated in single cages 30 min prior to the test. Each mouse was held 1 cm from the base of the tail and lifted forming an angle of 45 ° from the ground, allowing the support of the front limbs only. The animal was dragged backward and along a surface of 100 cm length at a constant speed of 20 cm/s for five consecutive times (each time alternating the direction of dragging). The animal was video recorded during the whole time. The number of each front limb stepping was counted later by two independent observers watching the videos at a slow pace 42, 43 . Drag test was evaluated 5 days before L-DOPA administration and days 3 and 16 after L-DOPA treatment (1 and 2 hr after injection).
Open Field
Open field test was used to determinate the total activity. Briefly, animals were placed in the of L-DOPA treatment 44, 45 .
Rotarod
The accelerating rotarod test was used to quantify the motor alterations in wild type and RasGRP1 KO mice. After placing the mice on the rotating rod (diameter of 5 cm), they were tested using the speed of the rotarod accelerated from 4 to 40 RPM over 5-min period and the total time spent on the rod was recorded. In order to identify the hemi-parkinsonian phenotype mice were test on the rotarod after 3 weeks of 6-OHDA lesion and the average of 3 trials was used for analysis. Rotarod evaluation during L-DOPA treatment were made at day 2 and 15, in each day mice were tested using one single trial at 0, 60 and 120 min after L-DOPA injection. In all the cases animals were not trained before the test 7, 46 .
Cell Culture, Transfections, Amino Acid Treatments and RasGRP1 shRNA experiments
HEK293 cells were cultured in growth medium containing DMEM (Thermo Fischer) with 10% FBS (fetal bovine serum), 1% pen strep, and 5 mM glutamine, essentially as described before 47, 48 . Cells seeded in 3.5-or 6-cm plates, after one day, were transfected with cDNA constructs using polyfect (Qiagen) as per the manufacturer's instructions. For the amino acid deprivation protocol, after 48 hr, the growth medium was replaced with either serum-free F12+ (D2906, Sigma) medium or F12-(D9785, Sigma) (without L-Leucine) medium for 2 hr, and, wherever indicated, F12-containing cells were stimulated with Leucine (3 mM) medium for the indicated time points, and cells were lysed to proceed with Western blotting. HEK293 cells were cultured in growth medium containing DMEM (Gibco 11965-092) with 10% FBS (fetal bovine serum), 1% pen strep, and 5 mM glutamine as described before 47, 48 Cells were seeded in 12-well plates for 1 day and then were transfected with RasGRP1 shRNA along with control shRNA constructs using polyfect (Qiagen), according to the manufacturer's instructions. The growth medium was removed after 24 hr and the cells were lysed to prepare for Western blotting.
Western blotting, in vivo binding experiments and recombinant protein purification
Protocol for Western blotting, glutathione-binding and Co-IP experiments in striatum was described in our previous studies 16, 47, 49 . GST-RasGRP1 proteins were expressed as described in our earlier work 6, 47, 50 .
In vitro binding
For the in vitro binding assay, an equimolar concentration of recombinant purified GST or GSTtagged RasGRP1 were incubated with Rheb for 16 hr at 4°C with glutathione beads in binding buffer containing 50 mM Tris/HCl (pH 8.2), 1 mM dithiothreitol, 100 mM NaCl, and 1% NP-40, and the Rheb was detected through Western blotting with a Rheb antibody, as described earlier 6, 16 .
TMT labelling, phosphopeptide enrichment and mass spectrometry experimental methods
Striatum from WT and RasGRP1-KO (see scheme Fig 4A) Proteomic data processing and statistical analysis were carried out as described before 52, 53 .
Statistical analysis:
Data were expressed as mean ± SEM as indicated. All experiments were performed at least in biological triplicate and repeated at least twice. Statistical analysis was performed with a Student's t-test or repeated measure two-way ANOVA followed by post-hoc Bonferroni multiple comparison test or one-way ANOVA followed by Tukey's multiple comparison test (Graphpad Prism7) as indicated in the figure legends. Figure 5 
